Background Information

The market for diabetes-related products is huge and continuing to grow. However, it is not the same market as it was just three years ago. New trends in care, new products, new approaches to long term complications, and changing public health priorities along with geographic variations are shifting the sands of opportunities in diabetes care. - Kalorama Information 2007

Type II or adult onset, diabetes, is the most widespread form of diabetes and with number of cases predicted by the International Diabetes Federation to be at 380 million by the year 2025 - Who will be the key players in the diabetes market? What kind of strategies are these companies using for their sales development and product lifecycle management? Will the oral anti-diabetics drugs and insulin still dominate the diabetes market and how will they compete with new innovated ideas being driven forward by the demanding diabetes market?

With diabetes expected to present one of the 21st century’s biggest medical challenges - What new research is being discovered that is linking diabetes with other medical conditions? The alarming increase of diabetes prevalence is projected to occur because of population aging, unhealthy diet, being over weight, obesity and sedentary lifestyle. The death rate in a diabetic person is 2 times higher than people without the disease.

With millions of pounds being invested in diabetes and as it stands currently without a cure... Who in the Diabetes market is fast tracking with innovated research and advancing formulations?

By attending visiongain’s 5th Annual Diabetes Conference, you will be a key participant in the journey of Diabetes. Our aim is to deliver, not only the best revolutionary technologies your company deserves, but provide you with the steps for advancement within the market.

5 Key reasons why you will not want to miss out:
1. Learn first-hand from the eminent industry and academic leaders in the diabetes market, and hear their analysis on productivity improvements
2. You will be provided with the results of robust research, and receive invaluable insights into the biopharmaceutical innovations that are leading the way forward
3. Stay ahead of the latest trends in pricing and reimbursement of the diabetes market
4. Be aware of what is driving the competitive edge in the diabetes market, and how you and your company will play a part
5. Take advantage of networking opportunities, which will only enhance your reputation as a key player in the diabetes journey of discovery

Key Themes:

• The global diabetes market has seen a high level of innovation, particularly in non-invasive methods of insulin delivery, including inhalable, oral and patch technology. These non-invasive methods are seen as favorable by patients and are likely to result in an increase in compliance, thus improving glycaemia control and leading to a reduction in diabetic complications

• What drug classes within the diabetes market are outperforming and underperforming the current market sales growth and why this is happening

• Analysing diabetic neuropathy and the affects this has on the nerves throughout the Body- How new advancing formulations are lowing the blood glucose levels, so protecting the nerves throughout the body

• What strategies are the leading companies implementing to protect off patent drugs and extend product lifecycles?

• Specific country breakdown of the market and examine the major companies involved in the market, in terms of their products, sales and strategic measures

• What could the future brings for stem cell therapies and how legislation is having effect on advancing scientific findings

Key Speakers

• Dr Andrew G. Swick, Director, Cardiovascular & Metabolic Diseases, Pfi zer

• Dr James Bainbridge, Consultant Ophthalmologist, Moorfi elds Eye Hospital

• Peter Damsbo, Managing Director, Damsbo

• Dr Yasser Abdel- Wahab, Senior Lecturer in Biomedical Sciences, University of Ulster

• Daniel Crockett, Managing Editor, Diabetes.co.uk

• Martin Walter, Partner, Simon-Kucher & Partners

• Professor Michael Cawthrone, Professorial Research Fellow and Director of Metabolic Research, Clore Laboratory, University of Buckinghamshire

• Professor David Heal, Director, RenaSci Consultancy

• Donny Wong, Principal Analyst, Cardiovascular & Metabolic Disorders, Decision Resources

• Dr Roger New, Chief Scientist, Diabetology

• Dr Costanza Emanueli, Reader of Experimental Cardiovascular and Medicine, Bristol University

• Professor David Dunger, Professor of Paediatrics, University of Cambridge

Who will be there?
Companies:
Pharmaceutical and Biotech
Academics Research Organisations
Regulatory Organisations
Trade Organisations
Healthcare Professionals
Hospitals

VP's, Directors, Heads and Management of:

• Endocrinology & Metabolism

• Cardiovascular & Metabolic Diseases

• Diabetes & Obesity, Clinical R&D

• New Antidiabetic Agents

• Metabolic Disease Research

• Advanced Diabetes Systems

• Department of Metabolic Research

• Chief Scientific Officer

• New Products Global Marketing

• Licensing and Partnering

• Drug Discovery

• Drug Development

• Regulatory Affairs

• Business Development

• Principle Investigators

TOP

09:00 Registration and refreshments

09:30 Opening address from chair

Dr Costanza Emanueli
Reader of Experimental Cardiovascular and Medicine
University of Bristol

09:40 The story with Leptin-aiding in T1 diabetes and obesity

• Insulin .V. Leptin- Who’s the leading contender?
• Leptin responsiveness in diet-Induced obesity
• The improved knowledge of Leptin, since being discovered in 1994
• Leptin receptors and their partnership with T cells activity in immune system

10:20 Amphibian skin secretions, a new approach for the treatment of Type 2 diabetes

• The innovation and determination behind the research of additional findings
• New class of medicines called incretin mimetics which mimic natural substances
• The next steps- More research is needed

Dr Yasser Abdel Wahab
Senior Lecturer in Biomedical Scientist
University of Ulster

11:00 Morning refreshments and networking opportunities

11:20 Role of the p75 neurotrophin receptor (p75NTR) in microvascular pathology

• These recent developments provide new insights into the functions of this enigmatic receptor
• Investigations into the development of new drugs to resist the effects p75NTR
• Beneficial effects of new drugs on one of the most devastating and life threatening complications associated with diabetes

Dr Costanza Emanueli
Reader of Experimental Cardiovascular and Medicine
University of Bristol

12:00 Update on Diabetology’s oral insulin product Capsulin®

• Oral insulin has many potential advantages over other forms of Insulin delivery
• Capsulin promises to be an exciting candidate for the improved treatment of the millions of sufferers of diabetes around the world

Dr Roger New
Chief Scientist
Diabetology

12:40 Networking Lunch

13:40 The use of Statins for all diabetic patients

• Reducing the risk of hearts attacks and strokes in diabetic patience
• Future discoveries how statins will have an effect of diabetes as a worldwide disease
• The benefits of Satins being prescribed to local authorities and the cost effectiveness as a whole

Professor David Dunger
Professor of Paediatrics
University of Cambridge

14:20 Online support communities - the positives and pitfalls of virtual diabetes communities
Diabetes.co.uk is growing as a community of diabetics and non-diabetics alike, offering their own support and first hand knowledge

Daniel Crockett
Managing Editor
Diabetes.co.uk

15:00 Afternoon refreshments

15:20 Pricing and reimbursement for diabetes drugs in Europe

• The latest trends in pricing and reimbursement of diabetes products
• Analysing the competitive market- What is driving the competitive edge within the diabetes market
• Value for money- What the consumers expect
• Understand how the diabetes pricing and reimbursement environment may evolve over the next five years

Martin Walter
Partner
Simon-Kucher & Partners

16:00 Current and future positioning of key competitors in the type 2 diabetes market

• Factors driving the shift in standard of care and innovation in diabetes
• Emerging therapies—which ones best address today’s needs?
• The future of DPP-IV inhibitors for type 2 diabetes

Donny Wong
Principal Analyst, Metabolic and Cardiovascular Disorders
Decisions Resources

16:40 Closing remarks from the chair

16:50 Networking Drinks Reception
Take your discussions further and build new relationships in a relaxed and informal setting

TOP

09:00 Registration and refreshments

09.30 Opening address from the chair
Professor David Heal
Director
RenaSci Consultancy

09:40 Using stem cell transplants to treat type I diabetes
Dr Richard Burt
Associate Professor, Division of Immunotherapy
North Western University*

10:20 Opportunities and challenges for the development of pharmacological therapies for diabetes treatment

• The metabolic effects of tetrahydrocannabivarin (THCV) and cannabidiol (CBD)
• Developmental origins of metabolic disease and the programming of physiological processes
• Acute and chronic studies including POC

Professor Michael Cawthrone
Professional Research Fellow & Director of Metabolic Research, Clore Laboratory
University of Buckinghamshire

11:00 Morning refreshments and networking opportunities

11:20 Pharmacological strategies for targeting the endocannabinoid system

• Exploring and validating Cannabinoid receptor, CB 1 and CB 2, in clinical trials
• New targets for obesity pharmacotherapy
• Phase III of CP-945598- CB-1 receptor for the treatment of obesity

Dr Andrew G. Swick
Director of Cardiovascular & Metabolic Disease
Pfizer

12:00 Developing business opportunities through improved relationships with healthcare providers

• Understanding the market needs for treatment of obesity and the relationship with Type 2 diabetes
• Demonstrating the economic and humanistic benefits of future diabetes therapies
• Impact of emerging information/data in relation to new findings

Senior Representative
IMS Health

12:40 Networking Lunch

13:40 Diabetic retinopathy and new therapeutic approaches
Moorfield Eye Hospital NHS Foundation Trust is one of the worlds leading centres for eye health

James Bainbridge
Consultant Ophthalmologist
Moorfields Eye Hospital

14:20 New research into a viable role for anti-obesity drugs in the treatment of type 2 diabetes

• A realistic assessment of the contribution of moderate weight-loss to improving glycaemic control in diabetic patience
• Updated findings into route regulatory approval for metabolic drugs
• New approaches of combination therapy with anti-obesity and anti-diabetic drugs to maximise clinical benefit in the treatment of type II diabetes

Professor David Heal
Director
RenaSci Consultancy

15:00 Afternoon refreshments and networking opportunities

15:20 The human placenta in gestational diabetes mellitus

• Comparing the cell profiles from normal and diseased placentas
• Evidence into that disease such as diabetes can start from the placenta
• Adipokines are key players in the regulation of insulin action between placenta and adipose tissue
• Intensive research into insulin secretagogues

Professor David Simmons
Lead Community Diabetologist
Wolfson Diabetes and Endocrinology Clinic*

16:00 Chair’s closing remarks

16:30 End of conference

TOP